Bernhard Eggimann
Corporate Officer/Principal bei Enobia Pharma, Inc.
Aktive Positionen von Bernhard Eggimann
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Enobia Pharma, Inc.
 Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Corporate Officer/Principal | 09.12.2010 | - |
Karriereverlauf von Bernhard Eggimann
Statistik
International
| Kanada | 2 |
Operativ
| Corporate Officer/Principal | 1 |
Sektoral
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Health Technology |
- Börse
- Insiders
- Bernhard Eggimann
- Erfahrung
